...
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives.
【24h】

Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives.

机译:咪唑和其他咪唑-苯并二氮杂羧酰胺衍生物的抗惊厥,抗焦虑和非镇静作用。

获取原文
获取原文并翻译 | 示例

摘要

Recent evidence suggests that alpha1-containing GABA(A) receptors mediate the sedative, amnestic, and to some extent the anticonvulsant actions of non-selective benzodiazepine (BZ) receptor ligands, such as diazepam (DZ). Anxiolytic and in part, anticonvulsant actions of BZ ligands are mediated by alpha2-, alpha3-, and alpha5-containing GABA(A) receptors. This has resulted in increasing interest in developing BZ ligands with selective actions at GABA(A) receptors, including alpha2-, alpha3-, and alpha5-subunits, but devoid of efficacy at alpha1-containing receptors. To refine their spectrum of pharmacological actions, efforts are being made to minimize unwanted effects such as sedation, amnesia, and tolerance liabilities. A prototype for such BZ ligands is imidazenil (IMD), an imidazo-benzodiazepine carboxylic acid derivative that elicits potent anticonvulsant and anxiolytic actions at doses virtually devoid of sedative, cardio-respiratory depressant and amnestic effects, and anticonvulsant tolerance liability. To define the pharmacological profile of IMD and its derivatives, we compared the anticonflict (anxiolytic), anti-proconflict (antipanic), anti-bicuculline (BIC), and maximal electroshock seizure (MES) effects, and the suppression of locomotor activity by imidazo-benzodiazepine carboxylic acid derivatives to those of DZ and bretazenil (BTZ). We report here that IMD and one of its derivatives (RO 25-2775) possess dose-dependent anticonflict, anti-proconflict, and anti-BIC actions but failed to suppress locomotor activity. Like DZ, the other IMD derivatives (enazenil, RO 25-2776, and RO 25-2847) not only elicit dose-dependent anticonflict, anti-proconflict, anti-BIC, anti-MES effects but also suppress locomotor activity. In contrast, none of the IMD derivatives studied shows any similarity to BTZ, which elicits anticonflict, anti-proconflict actions and suppresses locomotor activity but is virtually inactive against BIC-induced tonic-clonic convulsions.
机译:最近的证据表明,含alpha1的GABA(A)受体介导非选择性苯并二氮杂(BZ)受体配体(例如地西epa(DZ))的镇静,记忆消除和某种程度的抗惊厥作用。 BZ配体的抗焦虑和部分抗惊厥作用是由含α2,α3和α5的GABA(A)受体介导的。这导致人们对开发对GABA(A)受体具有选择性作用的BZ配体的兴趣日益增加,这些受体包括α2,α3和α5亚基,但对含α1的受体却缺乏功效。为了完善其药理作用范围,人们正在努力将诸如镇静,健忘和耐受性不良等不良影响降至最低。这种BZ配体的原型是咪唑西尼(IMD),一种咪唑-苯并二氮杂烷羧酸衍生物,在几乎没有镇静,心脏呼吸抑制和记忆消除作用的剂量下,会引发强效的抗惊厥和抗焦虑作用,并具有抗惊厥耐受性。为了定义IMD及其衍生物的药理学特征,我们比较了抗冲剂(抗焦虑药),抗冲剂(抗惊慌药),抗碧藻碱(BIC)和最大电击惊厥(MES)的作用,以及咪唑对运动活性的抑制作用-DZ和bretazenil(BTZ)的-苯并二氮杂羧酸衍生物。我们在此报告,IMD及其衍生物之一(RO 25-2775)具有剂量依赖性的抗冲突,抗冲突和抗BIC作用,但未能抑制运动活性。像DZ一样,其他IMD衍生物(依那西尼,RO 25-2776和RO 25-2847)不仅引起剂量依赖性抗冲突,抗冲突,抗BIC,抗MES作用,而且还抑制了运动活性。相反,所研究的IMD衍生物均未显示与BTZ的相似性,后者可引发抗冲突,抗冲突作用并抑制运动活性,但实际上对BIC引起的强直阵挛性抽搐无效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号